Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Dermatologic 2CNS 2Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 114Carcinoma, Non-Small-Cell Lung 34Neoplasms 26Neoplasm Metastasis 19Prostatic Neoplasms 18Uveal Melanoma 16Carcinoma, Renal Cell 16Lung Neoplasms 14Pancreatic Neoplasms 13Diabetes Mellitus, Insulin-Dependent, 12 12Small Cell Lung Carcinoma 11Colorectal Neoplasms 10Carcinoma, Hepatocellular 9Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Sarcoma 7Carcinoma, Transitional Cell 7Brain Neoplasms 7Stomach Neoplasms 6Mesothelioma 6Kidney Neoplasms 6Head and Neck Neoplasms 6Advanced Cancer 6Urinary Bladder Neoplasms 5Recurrence 5Ovarian Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma 5Leukemia, Myeloid, Acute 5

Interventions

Ifosfamide 17Methotrexate 16Doxorubicin 14Filgrastim 13Etoposide 12Cisplatin 12Cyclophosphamide 10Gemcitabine 9Leucovorin 8Sirolimus 6Carboplatin 6Topotecan 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Temozolomide 4Sorafenib 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Docetaxel 4trimetrexate glucuronate 3temsirolimus 3dinutuximab 3cixutumumab 3apatinib 3Vincristine 3Specimen Handling 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Osteosarcoma × Ipilimumab × Clear all
NCT05302921 2025-01-01

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Children's National Research Institute

Phase 2 Completed
5 enrolled
CNSDermatologicGastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Melanoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡